Publications by authors named "David DeRemer"

Claim this Profile
Z
Zolbetuximab-clzb: Targeting Claudin 18.2 in Advanced Gastric and Gastroesophageal Adenocarcinoma.
Gabrielle L Gorwitz, David L DeRemer

Ann Pharmacother· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Severe toxicity following genotype-guided reduced 5-FU dose in a heterozygous DPYD c.2846A>T carrier with stage III anal carcinoma: A case report.
Madeline L Norris, David L DeRemer, Julio D Duarte, George P Kim, Thomas J George

Cancer Chemother Pharmacol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Racial Disparities in Analgesic and Psychiatric Medication Use During End-Of-Life Care in Advanced-Stage Colorectal Cancer: A Retrospective Cohort Study.
John M Allen, Olga M Trejos Kweyete, Yi Guo, Jiang Bian, Xiwei Lou, David L DeRemer

Cancer Res Commun· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms.
Thomas J George, Ji-Hyun Lee, David L DeRemer, Peter J Hosein, Steven Staal

JCO Precis Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Capivasertib: A Novel AKT Inhibitor Approved for Hormone-Receptor-Positive, HER-2-Negative Metastatic Breast Cancer.
Alexa J Luboff, David L DeRemer

Ann Pharmacother· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms.
Thomas J George, Ji-Hyun Lee, David L DeRemer, Peter J Hosein, Steven Staal

JCO Precis Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementation of a pharmacogenetic panel-based test for pharmacotherapy-based supportive care in an adult oncology clinic.
Emily J Cicali, Elizabeth Eddy, Yan Gong, Amanda L Elchynski, Kim Pena Del Aguila, David L DeRemer

Clin Transl Sci· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Research summary of poster presentations at the 2023 Florida cardio-oncology symposium.
Katelyn A Bruno, Walter G O'Dell, Marwa Tantawy, Camara L Casson, Meghan C Ferrall-Fairbanks, David L DeRemer

Am Heart J Plus· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unraveling Racial Disparities in Supportive Care Medication Use among End-of-Life Pancreatic Cancer Patients: Focus on Pain Management and Psychiatric Therapies.
John M Allen, MegCholack Awunti, Yi Guo, Jiang Bian, Sherise C Rogers, David L DeRemer

Cancer Epidemiol Biomarkers Prev· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma.
Ruchi Singhal, Sherise C Rogers, Ji-Hyun Lee, Brian Ramnaraign, Ilyas Sahin, David L DeRemer

Future Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adverse Cardiovascular Events Associated With Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Metastatic Breast Cancer.
Michael G Fradley, Nam H K Nguyen, David Madnick, Yiqing Chen, Angela DeMichele, David DeRemer

J Am Heart Assoc· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Racial and Ethnic Differences in Cardiac Surveillance Evaluation of Patients Treated With Anthracycline-Based Chemotherapy.
David L DeRemer, Nam K Nguyen, Avirup Guha, Faraz S Ahmad, Rhonda M Cooper-DeHoff

J Am Heart Assoc· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans.
Guettchina Telisnor, David L DeRemer, Esther Frimpong, Edward Agyare, John Allen

J Natl Med Assoc· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating Treatment Options and the Multidisciplinary Care of Ocular Toxicities of MEK Inhibitors.
David L DeRemer, Bently P Doonan

Oncology (Williston Park)· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of coronavirus of 2019 on the delivery of pharmacy services to patients with cancer: An international survey of oncology pharmacy practitioners.
Grace Chazan, Jennifer Jupp, Tiene Bauters, Nick Duncan, Kellie Jones Weddle, David L DeRemer

J Oncol Pharm Pract· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Scoping Review on the Relationship between Race/Ethnicity and the Receipt of Supportive Care Medications during Cancer Treatment: Implications for the Clinical Pharmacist.
MegCholack Awunti, David L DeRemer, Sherise Rogers, Lisa Scarton, Lauren Adkins

J Am Coll Clin Pharm· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab plus tivozanib for immunologically cold tumor types: the IMMCO-1 trial.
Brian H Ramnaraign, Ji-Hyun Lee, Azka Ali, Sherise C Rogers, Jesus C Fabregas, David L DeRemer

Future Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiometabolic Consequences of Targeted Anticancer Therapies.
Avirup Guha, Yan Gong, David DeRemer, Jocelyn Owusu-Guha, Susan F Dent

J Cardiovasc Pharmacol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
National Survey on the Effect of Oncology Drug Shortages in Clinical Practice: A Hematology Oncology Pharmacy Association Survey.
Ali McBride, Sarah Hudson-DiSalle, Jeff Pilz, Mark Hamm, Brooke Boring, David L DeRemer

JCO Oncol Pract· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emergence of ocular toxicities associated with novel anticancer therapeutics: What the oncologist needs to know.
Azka Ali, Ankit A Shah, Lauren J Jeang, Kyle S Fallgatter, Thomas J George, David L DeRemer

Cancer Treat Rev· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinically Relevant Drug Interactions in the Cancer Setting.
David DeRemer

J Adv Pract Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review.
Ziyan Chen, Yue Cheng, David DeRemer, Vakaramoko Diaby

Expert Rev Pharmacoecon Outcomes Res· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of 5-Fluorouracil, Oxaliplatin plus Dasatinib (FOLFOX-D) in First-Line Metastatic Pancreatic Adenocarcinoma.
Thomas J George, Azka Ali, Yu Wang, Ji-Hyun Lee, Alison M Ivey, David DeRemer

Oncologist· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lactate Dehydrogenase B and Pyruvate Oxidation Pathway Associated With Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients: Result of a Multi-Omics Integrative Analysis.
Marwa Tantawy, Lakshmi Manasa Chekka, Yimei Huang, Timothy J Garrett, Sonal Singh, David L DeRemer

Front Cardiovasc Med· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center.
Nida Waheed, Michael G Fradley, David L DeRemer, Ahmad Mahmoud, Chintan P Shah

Cardiooncology· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis